AL-102 is a Small Molecule owned by Ayala Pharmaceuticals, and is involved in 3 clinical trials, of which 2 are ongoing, and 1 is planned.
BMS-986115 (AL-102) acts by inhibiting gamma-secretase. Gamma secretase plays a major role in the activation of Notch signalling pathway that is responsible for the progression of cancer and in increased production of B-cell maturation antigen (BCMA). The drug candidate binds to GS and blocks the proteolytic activation of Notch receptors and decrease the BCMA leading to the induction of apoptosis in tumor cells.
The revenue for AL-102 is expected to reach a total of $678m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the AL-102 NPV Report.
BMS-986115 (AL-102) is under development for the treatment of desmoid tumors, relapsed and refractory T-cell acute lymphoblastic leukemia (T-ALL) and relapsed/refractory multiple myeloma. It is administered orally. The drug candidate is a pan-notch gamma secretase inhibitor.
It was under development for the treatment of advanced solid tumors
Ayala Pharmaceuticals Overview
Ayala Pharmaceuticals is a clinical-stage bio-pharmaceutical company which develops novel drugs for defined cancers. Its lead product candidate AL101 and AL102 to treat cancers. The products render different cancers like desmoid tumors, adenoid cystic carcinoma (ACC), triple negative breast cancer (TNBC) and T-cell acute lymphoblastic leukemia (T-ALL). Ayala Pharmaceuticals desmoid tumors arise in upper and lower extremities, abdominal wall, head and neck area, mesenteric root and chest wall of the body. In addition, it also focuses on inhibiting the Notch activating pathway with best-in-class gamma secretase inhibitors (GSIs). The company has operations in Israel and the US. Ayala Pharmaceuticals is headquartered in Wilmington, Delaware, the US.
The company reported revenues of (US Dollars) US$3.5 million for the fiscal year ended December 2021 (FY2021), a decrease of 5.4% over FY2020. The operating loss of the company was US$39.2 million in FY2021, compared to an operating loss of US$29.8 million in FY2020. The net loss of the company was US$40.3 million in FY2021, compared to a net loss of US$30.2 million in FY2020.
Quick View – AL-102
|Highest Development Stage|